COMP <GO>
PLRX vs TLPH // NET PROFIT MARGIN
Pliant Therapeutics Inc. (NASDAQ) VS. Talphera Inc. (NASDAQ) • 15-METRIC TALLY: PLRX 1
— TLPH 1
■ METRIC PARITY
LAST: $0.84 (-2.29%) • MKT CAP: $53.2M
net-margins
—
LAST: $1.01 (-1.94%) • MKT CAP: $53.5M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLRX VS. TLPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PLRX | TLPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -20.46% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 34.6 | +0.70 | PLRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $53.2M | $53.5M | -$278.3K | TLPH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PLRX REV | TLPH REV | PLRX GROSS % | TLPH GROSS % | PLRX FCF | TLPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $437.8M | $37.8M | — | — | -$128.7M | -$11.4M |
| FY 2024 | $639.4M | $42.7M | — | — | -$159.4M | -$12.7M |
| FY 2023 | $1.6M | $47.3M | — | — | -$116.4M | -$17.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLRX // BETA —
TLPH // BETA —